Jessen Frank, Amariglio Rebecca E, van Boxtel Martin, Breteler Monique, Ceccaldi Mathieu, Chételat Gaël, Dubois Bruno, Dufouil Carole, Ellis Kathryn A, van der Flier Wiesje M, Glodzik Lidia, van Harten Argonde C, de Leon Mony J, McHugh Pauline, Mielke Michelle M, Molinuevo Jose Luis, Mosconi Lisa, Osorio Ricardo S, Perrotin Audrey, Petersen Ronald C, Rabin Laura A, Rami Lorena, Reisberg Barry, Rentz Dorene M, Sachdev Perminder S, de la Sayette Vincent, Saykin Andrew J, Scheltens Philip, Shulman Melanie B, Slavin Melissa J, Sperling Reisa A, Stewart Robert, Uspenskaya Olga, Vellas Bruno, Visser Pieter Jelle, Wagner Michael
Department of Psychiatry, University of Bonn, Bonn, Germany; Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.
There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus.
越来越多的证据表明,认知测试表现未受损的个体出现的主观认知下降(SCD)可能是阿尔茨海默病(AD)的首个症状表现。然而,早期AD中SCD的研究因缺乏通用标准而受到限制。主观认知下降倡议组织(SCD - I)的工作组通过就术语以及AD中SCD研究的概念框架达成共识,解决了这一缺陷。在本出版物中,提出了轻度认知障碍(MCI)前期SCD的研究标准。此外,还提供了一份建议在SCD研究中报告的核心特征列表,这将使不同研究背景下的研究具有可比性。最后,列出了一组特征,根据当前知识,这些特征增加了SCD个体中存在临床前AD的可能性。此列表称为SCD加。